Abstract
TUG1 is an lncRNA that plays a critical role in kidney injury. Our preliminary sequencing analysis showed altered TUG1 expression in both congestive heart failure (CHF) patients and CHF patients complicated with chronic kidney disease (CKD). We then studied the role of TUG1 in these two diseases. We enrolled 120 CHF patients without obvious complications, 60 CHF patients complicated with CKD, and 60 healthy volunteers. TUG1 expression in plasma samples from these participants was determined using RT-qPCR. The diagnostic value of TUG1 for CKD development in CHF patients was evaluated by ROC curve analysis. A 2-year follow-up was performed to detect the correlation between TUG1 expression levels and the development of CKD in CHF. TUG1 was lowly expressed in CHF patients and was further downregulated in CHF patients complicated with progressive CKD. ROC curve analysis showed that plasma TUG1 expression levels could be used to distinguish CHF patients complicated with CKD from CHF patients without CKD and healthy controls. During the 2-year follow-up, high CHF expression levels predicted a low incidence of progressive CKD among CHF patients. With the treatment of progressive CHF + CKD, plasma TUG1 was upregulated. LncRNA-TUG1 downregulation may develop the progressive CKD among patients with CHF.
Similar content being viewed by others
References
Stein, P., & Pu, Y. (2012). Heart rate variability in congestive heart failure. In: Heart Rate Variability (HRV) signal analysis (pp. 303–324). CRC Press.
Javaheri, A., Shewale, S., Frej, C., Liu, M., Bedi, K., Brandimarto, J., Mu, A., Wang, T., Chen, C. Y., & Ma, X. (2016). Apolipoprotein M improves survival in congestive heart failure via enhanced Akt signaling. Journal of Cardiac Failure, 22(8), S1.
Tran, H. A., Lin, F., & Greenberg, B. H. (2016). Potential new drug treatments for congestive heart failure. Expert Opinion on Investigational Drugs, 25(7), 811–826.
Damman, K., & Testani, J. M. (2015). The kidney in heart failure: An update. European Heart Journal, 36(23), 1437–1444.
Jungbauer, C. G., Birner, C., Jung, B., Buchner, S., Lubnow, M., von Bary, C., Endemann, D., Banas, B., Mack, M., Boger, C. A., Riegger, G., & Luchner, A. (2011). Kidney injury molecule-1 and N-acetyl-beta-D-glucosaminidase in chronic heart failure: Possible biomarkers of cardiorenal syndrome. European Journal of Heart Failure, 13(10), 1104–1110.
Kovesdy, C. P., Lott, E. H., Lu, J. L., Malakauskas, S. M., Ma, J. Z., Molnar, M. Z., & Kalantar-Zadeh, K. (2012). Hyponatremia, hypernatremia, and mortality in patients with chronic kidney disease with and without congestive heart failure. Circulation, 125(5), 677–684.
Popolo, A., Autore, G., Pinto, A., & Marzocco, S. (2013). Oxidative stress in patients with cardiovascular disease and chronic renal failure. Free Radical Research, 47(5), 346–356.
Quinn, J. J., & Chang, H. Y. (2016). Unique features of long non-coding RNA biogenesis and function. Nature Reviews Genetics, 17(1), 47–62.
Engreitz, J. M., Ollikainen, N., & Guttman, M. (2016). Long non-coding RNAs: Spatial amplifiers that control nuclear structure and gene expression. Nature Reviews Molecular Cell Biology, 17(12), 756–770.
Lorenzen, J. M., & Thum, T. (2016). Long noncoding RNAs in kidney and cardiovascular diseases. Nature Reviews. Nephrology, 12(6), 360–373.
Santer, L., Lopez, B., Ravassa, S., Baer, C., Riedel, I., Chatterjee, S., Moreno, M. U., Gonzalez, A., Querejeta, R., Pinet, F., Thum, T., & Diez, J. (2019). Circulating long noncoding RNA LIPCAR predicts heart failure outcomes in patients without chronic kidney disease. Hypertension, 73(4), 820–828.
Zhou, H., Wang, B., Yang, Y. X., Jia, Q. J., Zhang, A., Qi, Z. W., & Zhang, J. P. (2019). Long noncoding RNAs in pathological cardiac remodeling: A review of the update literature. BioMed Research International, 2019, 7159592.
Hobuß, L., Bär, C., & Thum, T. (2019). Long non-coding RNAs: At the heart of cardiac dysfunction? Frontiers in Physiology. https://doi.org/10.3389/fphys.2019.00030
Moreno, J. A., Hamza, E., Guerrero-Hue, M., Rayego-Mateos, S., García-Caballero, Vallejo-Mudarra, M., Metzinger, L., & Metzinger-Le Meuth, V. (2021). Non-coding RNAs in kidney diseases: The long and short of them. International Journal of Molecular Sciences, 22(11), 6077.
Liu, X., Hong, C., Wu, S., Song, S., Yang, Z., Cao, L., Song, T., & Yang, Y. (2019). Downregulation of lncRNA TUG1 contributes to the development of sepsis-associated acute kidney injury via regulating miR-142-3p/sirtuin 1 axis and modulating NF-kappaB pathway. Journal of Cellular Biochemistry.
Li, J., Zhang, M., An, G., & Ma, Q. (2016). LncRNA TUG1 acts as a tumor suppressor in human glioma by promoting cell apoptosis. Experimental Biology and Medicine (Maywood, NJ), 241(6), 644–649.
Yun-Bo, F., Xiao-Po, L., Xiao-Li, L., Guo-Long, C., Pei, Z., & Fa-Ming, T. (2016). LncRNA TUG1 is upregulated and promotes cell proliferation in osteosarcoma. Open Med (Wars), 11(1), 163–167.
Chen, S., Wang, M., Yang, H., Mao, L., He, Q., Jin, H., Ye, Z. M., Luo, X. Y., Xia, Y. P., & Hu, B. (2017). LncRNA TUG1 sponges microRNA-9 to promote neurons apoptosis by up-regulated Bcl2l11 under ischemia. Biochemical and Biophysical Research Communications, 485(1), 167–173.
Xu, Y., Ge, Z., Zhang, E., Zuo, Q., Huang, S., Yang, N., Wu, D., Zhang, Y., Chen, Y., Xu, H., Huang, H., Jiang, Z., & Sun, L. (2017). The lncRNA TUG1 modulates proliferation in trophoblast cells via epigenetic suppression of RND3. Cell Death & Disease, 8(10), e3104.
Schefold, J. C., Filippatos, G., Hasenfuss, G., Anker, S. D., & von Haehling, S. (2016). Heart failure and kidney dysfunction: Epidemiology, mechanisms and management. Nature Reviews Nephrology, 12(10), 610–623.
Unger, E. D., Dubin, R. F., Deo, R., Daruwalla, V., Friedman, J. L., Medina, C., Beussink, L., Freed, B. H., & Shah, S. J. (2016). Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 18(1), 103–112.
Zhang, W., Zhou, X., Zhang, H., Yao, Q., Liu, Y., & Dong, Z. (2016). Extracellular vesicles in diagnosis and therapy of kidney diseases. American Journal of Physiology. Renal Physiology, 311(5), F844–F851.
Metzinger-Le Meuth, V., Fourdinier, O., Charnaux, N., Massy, Z., & Metzinger, L. (2019). The expanding roles of microRNAs in kidney pathophysiology. Nephrology Dialysis Transplantation, 34(1), 7–15.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Zhao, W., Zhang, Y., Zhang, M. et al. LncRNA-TUG1 Downregulation is Correlated with the Development of Progressive Chronic Kidney Disease Among Patients with Congestive Heart Failure. Mol Biotechnol 64, 493–498 (2022). https://doi.org/10.1007/s12033-021-00427-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12033-021-00427-3